Best Grants for HIV / AIDS in Northern Mariana Islands

The National Institute of Mental Health is inviting research applications for the AIDS Research Center program, which includes Developmental Centers and full Research Centers. This initiative aims to enhance interdisciplinary HIV/AIDS research through collaboration and innovative approaches across various scientific domains. The program emphasizes alignment with national strategies and encourages applications from teams skilled in fostering partnerships with diverse stakeholders. Although applications are currently not being solicited, this notice allows potential applicants time to prepare strong proposals.

This funding opportunity aims to advance HIV/AIDS research by implementing human new approach methodologies (NAMs) to reduce the reliance on specific pathogen free (SPF) animal models. It emphasizes the integration of NAMs-enabled frameworks for in vitro testing while supporting essential SPF colony resources. The initiative seeks to enhance research rigor and reproducibility through innovative strategies that prioritize human-relevant models, ultimately improving HIV research outcomes and facilitating collaborative development in the field.

The National Institute of Allergy and Infectious Diseases (NIAID) is calling for applications for four Leadership and Operations Centers (LOCs) as part of its HIV/AIDS Clinical Trials Network initiative. These LOCs will guide research on HIV therapeutics, prevention, and treatment strategies across diverse populations. The initiative aims to enhance evidence-based practices and improve health outcomes for individuals affected by HIV, ultimately contributing to the goal of ending the HIV epidemic.

The National Institute of Allergy and Infectious Diseases (NIAID) is launching a funding opportunity for up to four Clinical Trials Network Laboratory Centers (LCs). These LCs will support HIV prevention and treatment strategies by providing necessary laboratory infrastructure and technologies for clinical trials. They will ensure rigorous laboratory testing and oversight, enhance sample integrity, and utilize advanced data management systems to meet evolving demands in HIV research and testing.

The NIAID aims to support four Clinical Trials Networks (CTNs) by funding Statistical and Data Management Centers (SDMCs) to enhance HIV research. These SDMCs will oversee study designs, data collection, and compliance with regulatory standards while ensuring data quality and integration. This initiative is a crucial step toward ending the HIV epidemic, fostering innovative methods, and adhering to NIH data sharing policies. Applications for the SDMCs are now being solicited.

The National Institute of Allergy and Infectious Diseases (NIAID) is launching a funding opportunity for Clinical Trials Units (CTUs) as part of its effort to combat HIV/AIDS. This initiative aims to support innovative clinical trials and implementation research to improve prevention and treatment strategies. With a focus on both domestic and international research sites, CTUs will play a crucial role in addressing the HIV epidemic and enhancing participant recruitment and retention. This funding opportunity is authorized under the Public Health Service Act.

The Centers for Structural Biology of HIV and Other Infectious Diseases aims to support innovative frontier science research that establishes new technologies and methodologies to provide insight into the mechanisms of hostpathogen interactions, as well as translational research to inform the development of novel and/or improved preventive interventions, therapeutics, diagnostics, and curative interventions across a broad spectrum of infectious diseases. These Centers focus on understanding the dynamics of molecular complexes, with the intention of informing mechanistically based discovery and/or design of interventions for the prevention, treatment, and cure of HIV and other infectious diseases. The goal is to facilitate the discovery of new therapeutic targets, new classes of interventions ranging from diagnostics, to small molecules and protein therapeutics, to neutralizing antibodies, and novel vaccine candidates, including nanoparticle vaccines, elucidate the mechanisms of action of interventions, and to determine the structural basis for interventional failures, but not support end-to-end preclinical development.

Of particular interest are the components of infectious agents and/or hosts for which sufficiently complete structureshave yet to be determined, including macromolecular complexes of proteins, nucleic acids, carbohydrates, lipid membranes, and/or small molecules. The Centers will be responsible for the validation of structural data using biological, biochemical, and computational methods and artificial intelligence (AI) models to help understand the biological mechanisms and structure-function relationships of these complexes.

The Ryan White HIV/AIDS Program (RWHAP) Integrated HIV/AIDS Planning Resource Allocation Cooperative Agreement aims to enhance the effectiveness of HIV prevention and care planning for RWHAP Parts A and B recipients. Through the provision of training, tools, and technical assistance, this initiative seeks to optimize resource allocation and strengthen the overall system of HIV care and treatment, ultimately improving health outcomes for those affected by HIV.

The US Dept. of Health & Human Services, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development, is set to announce a funding opportunity focused on HIV research for pediatric and maternal populations. This initiative aims to foster innovative clinical trials addressing critical research areas in HIV, inviting collaborations from experts in various fields. Applications are not currently solicited, but potential applicants are encouraged to prepare for this opportunity.

The Avant Garde Award supports innovative research on HIV and substance use disorders, encouraging creative scientists to explore high-risk, high-reward approaches. While applications are not currently being accepted, this initiative by the National Institute on Drug Abuse (NIDA) aims to stimulate collaborations and impactful research. Early-stage investigators are particularly encouraged to consider this opportunity as they develop their proposals for future funding. The program uses the DP1 activity code, fostering transformative advancements in biomedical and behavioral science.

This funding opportunity invites innovative pilot studies focused on biological, behavioral, and social mechanisms related to HIV pathogenesis, aligning with NIDDK's mission and NIH HIV/AIDS research priorities. Topics may include exploring pathophysiological mechanisms of HIV comorbidities and coinfections, understanding HIV reservoirs in relevant tissues, and examining social determinants affecting health outcomes. Applications are due by 5:00 PM local time of the applicant organization.

The Academic Research Enhancement Award (AREA) supports small-scale research grants for institutions with limited NIH funding, emphasizing biomedical research experiences for undergraduates. Eligible institutions must award baccalaureate science degrees and have received no more than $6 million in NIH support over the past seven years. This initiative aims to enhance the research environment at these institutions, fostering student involvement in research activities.

The High Priority HIV and Substance Use Research funding opportunity aims to support innovative research that addresses the intersection of HIV and substance use. Researchers are encouraged to submit proposals that include a detailed research plan and preliminary data, exploring new avenues for prevention, treatment, and potential cures for HIV among people who use drugs. Applications are due by 5 PM local time, with optional Letters of Intent recommended 30 days prior.

The AIDS Drug Assistance Program (ADAP) Emergency Relief Funds aim to provide essential funding to states and territories. This initiative focuses on preventing, reducing, or eliminating waiting lists for ADAP services, ensuring timely access to necessary medications and support for individuals living with HIV/AIDS. This program addresses critical funding shortfalls, enhancing the healthcare infrastructure and improving health outcomes in affected communities.

This funding opportunity aims to support Early Stage Investigators (ESIs) in conducting preclinical HIV/AIDS research using Nonhuman Primate (NHP) models. Eligible applicants must have at least two years of postdoctoral experience and be within ten years of their terminal degree. The initiative aligns with the NIH Strategic Plan for HIV and HIV-Related Research, targeting the reduction of HIV incidence, development of therapies, and advancement in research areas related to HIV.

The Ryan White HIV/AIDS Program Part C Capacity Development Program aims to enhance the capabilities of community-based organizations, focusing on improving health outcomes and decreasing HIV transmission. This initiative supports individuals who have not yet accessed regular HIV care, emphasizing innovative care solutions and infrastructure development to address these critical needs.

The HIV Care Grant Program, funded by the US HHS: Health Resources & Services Administration (HRSA), aims to enhance access to high-quality HIV care and treatment for low-income individuals. This initiative supports states and territories in developing comprehensive systems to address the needs of those living with HIV. By providing essential resources, the program seeks to improve health outcomes and ensure that vulnerable populations receive the necessary support and services.

The Ryan White HIV/AIDS Program Part B Supplemental Grant aims to provide essential funding to support HIV care and treatment services across states and territories. This program supplements existing formula-based funding from the RWHAP Part B and ADAP, improving access to necessary resources for those affected by HIV/AIDS. By enhancing support structures, it addresses critical healthcare needs, ensuring better health outcomes for vulnerable populations.

The HIV Care Grant Program aims to enhance access to comprehensive, high-quality HIV care and treatment for low-income individuals in Pacific Island territories. Funded by the US HHS: Health Resources & Services Administration (HRSA), this initiative supports states and territories in developing effective systems of care, ensuring that those affected by HIV receive the necessary treatment and support to improve health outcomes.

This funding opportunity aims to enhance a web-based ordering portal for distributing 1.5 million HIV and STI self-tests to high-burden communities. By optimizing access to these self-tests, the initiative seeks to raise awareness, prevent new infections, and improve the health outcomes of users, thereby contributing to better overall public health and wellbeing.

This project aims to enhance health outcomes for women living with HIV in the South by integrating HIV care with comprehensive women's health services through coordinated Clinic and Community Collaboratives. By funding organizations to implement targeted strategies such as culturally responsive services and learning collaboratives, the initiative seeks to improve access to essential health services, increase the number of women initiating rapid ART, and foster sustainable healthcare models that address the unique needs of this population.

The Ryan White HIV/AIDS Program Part D provides supplemental funding aimed at enhancing the infrastructure and capacity of organizations to deliver high-quality, family-centered HIV care services. This initiative focuses on two key areas: HIV Care Innovation and Infrastructure Development, ensuring improved access to essential services for women, infants, children, and youth affected by HIV.

The Ryan White HIV/AIDS Program Part B AIDS Drug Assistance Program Training and Technical Assistance aims to enhance the capacity of ADAPs. By providing essential tools and expert guidance, the program seeks to improve health outcomes for individuals living with HIV in an evolving healthcare landscape. This initiative is funded by the US HHS through the Health Resources & Services Administration, ensuring support and resources are effectively allocated to meet the needs of vulnerable populations.

The SCORCH Program: Phase 2 aims to enhance the understanding of single cell biology in the context of HIV and Substance Use Disorder (SUD). Building on previous research, this initiative will explore new single cell approaches to investigate the interactions between SUD and HIV progression at various biological levels. By leveraging advanced techniques, the program seeks to identify candidate mechanisms and potential therapeutic targets, ultimately contributing to innovative solutions for SUDs and HIV-related challenges.

The LAST MILE program, initiated by the NIAID, aims to enhance the implementation and effectiveness of HIV prevention and treatment strategies through real-world effectiveness trials. By fostering collaborations and focusing on diverse populations, this initiative seeks to translate clinical findings into practical applications. The program supports research across various disciplines, aligning with the NIH's mission to improve HIV/AIDS outcomes and address associated comorbidities. This multifaceted approach promises to bridge the gap between clinical trials and community-based interventions.

The HIV Prevention and Alcohol R61/R33 funding opportunity aims to advance innovative HIV prevention strategies through a phased research approach. The R61 phase focuses on developing and pilot testing interventions, addressing key implementation questions for diverse populations. Following successful milestones, the R33 phase expands testing of these interventions and explores their effectiveness and sustainability, particularly in relation to alcohol use and related health issues.

Gilead Sciences

At Gilead, we are relentlessly committed to advancing transformative therapies for the most serious diseases, delivering an exponentially positive impact on health.

For more than three decades, we have combined scientific rigor with a deep sense of purpose to improve health outcomes and reimagine care. Our work spans more than 35 countries with a focus on three therapeutic areas: virology, oncology, and inflammation, where unmet medical needs remain greatest.

From individual patients to whole populations, we’re committed to delivering healthier futures for people and communities worldwide.

Our Mission: To discover, develop and deliver innovative therapeutics for people with life-threatening diseases.

HIV Prevention NOVA 2026

Program Description

Gilead Sciences invites research proposals that advance the evidence base for innovative and scalable models of delivery for long-acting (LA) HIV pre-exposure prophylaxis (PrEP) in the United States.

This Topic of Interest (TOI) is focused on care delivery models implemented in non-traditional settings, defined as clinical and non-clinical environments where PrEP services are not routinely provided. Emphasis is placed on approaches that reflect real-life practice and address gaps in current PrEP delivery infrastructure.

Persistent inequities in PrEP uptake in the U.S. suggest that expanding availability within traditional clinical settings alone is unlikely to reach all populations with unmet PrEP need.1,2 Rigorous implementation studies in non-traditional settings where PrEP services are not routinely provided are needed to evaluate whether these models can reduce access barriers and improve equitable reach among individuals who may benefit from PrEP.2,3,4

The goal of this TOI is to generate practical, decision-relevant evidence that informs how LA PrEP can be implemented, scaled, and sustained in real-life U.S. settings.